[{"id":"1eb4bfe6-a419-4cd5-9ec6-57d058690b45","acronym":"","url":"https://clinicaltrials.gov/study/NCT01813539","created_at":"2021-01-18T08:03:00.872Z","updated_at":"2024-07-02T16:35:40.457Z","phase":"Phase 1/2","brief_title":"A Study of ARGX-110 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT01813539","lead_sponsor":"OncoVerity, Inc.","biomarkers":" CD70 • CD27","pipe":"","alterations":" ","tags":["CD70 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cusatuzumab (ARGX-110)"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 02/27/2013","start_date":" 02/27/2013","primary_txt":" Primary completion: 07/10/2020","primary_completion_date":" 07/10/2020","study_txt":" Completion: 07/10/2020","study_completion_date":" 07/10/2020","last_update_posted":"2023-08-09"},{"id":"b7b91d43-2908-4714-880d-0a8d2ca7e7e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03030612","created_at":"2021-01-18T14:55:03.502Z","updated_at":"2024-07-02T16:35:40.566Z","phase":"Phase 1/2","brief_title":"A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)","source_id_and_acronym":"NCT03030612","lead_sponsor":"OncoVerity, Inc.","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • cusatuzumab (ARGX-110)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2023-08-09"},{"id":"24c276d5-e174-42f2-ae14-0f6a5076d5fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02759250","created_at":"2021-01-18T13:31:50.817Z","updated_at":"2024-07-02T16:37:08.106Z","phase":"Phase 1","brief_title":"A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)","source_id_and_acronym":"NCT02759250","lead_sponsor":"argenx","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cusatuzumab (ARGX-110)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 04/25/2018","primary_completion_date":" 04/25/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-08-08"}]